title: A preliminary report on the intervention trials of primary liver cancer in high-risk populations with nutritional supplementation of selenium in China.
abstract: The purpose of this study was to evaluate the effect of selenium (Se) in the prevention of human primary liver cancer. Three intervention trials were conducted among the residents at high risk to primary liver cancer (PLC) in Qidong county, Jiang-su province, the People's Republic of China. This area has the second highest rate of PLC in China. One trial was undertaken among the general population in a township with supplement of table salt fortified with 15 ppm anhydrous sodium selenite (Se-salt) for 5 y and the other four townships with similar PLC incidence rate served as the controls using normal table salt. The second trial was undertaken among hepatitis B virus surface antigen carriers (HBVsAg+) receiving supplement of 200 micrograms Se in form of selenized yeast (Se-yeast) daily vs placebo for 4 y. The third trial was carried out in members of families with high PLC incidence using Se-yeast (200 micrograms of Se daily) vs placebo for 2 y. The results showed that nutritional supplement of Se could reduce the PLC incidence significantly.
authors.affiliation: Cancer Institute, Chinese Academy of Medical Sciences, Bejing.
authors.forename: S Y
authors.initials: SY
authors.lastname: Yu
authors.forename: Y J
authors.initials: YJ
authors.lastname: Zhu
authors.forename: W G
authors.initials: WG
authors.lastname: Li
authors.forename: Q S
authors.initials: QS
authors.lastname: Huang
authors.forename: C Z
authors.initials: CZ
authors.lastname: Huang
authors.forename: Q N
authors.initials: QN
authors.lastname: Zhang
authors.forename: C
authors.initials: C
authors.lastname: Hou
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002681:China / Q000453:epidemiology; D004261:DNA Replication / Q000187:drug effects; D005527:Food, Fortified; D006514:Hepatitis B Surface Antigens / Q000032:analysis*; D006801:Humans; D015994:Incidence; D008113:Liver Neoplasms / Q000453:epidemiology / Q000517:prevention & control*; D015162:Micronucleus Tests; D008875:Middle Aged; D012307:Risk Factors; D012643:Selenium / Q000008:administration & dosage / Q000627:therapeutic use*; D018038:Sodium Selenite; D015002:Yeast, Dried
chemical_list: D000970:Antineoplastic Agents; D006514:Hepatitis B Surface Antigens; D012643:Selenium; D018038:Sodium Selenite